Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19

Br J Haematol. 2020 Aug;190(4):e189-e191. doi: 10.1111/bjh.16962. Epub 2020 Jul 19.

Abstract

The optimal treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)/COVID‐19 is unknown.1 We report the case of a previously fit 27‐year‐old male who presented with a 3‐day history of fever (>39 C), swollen, erythematous elbows and no respiratory symptoms. His white blood count (WBC) was 187×109/L and bone marrow (Figure 1A & 1C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), wild‐type NPM1 and no additional mutations on a next‐generation sequencing panel.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aniline Compounds / administration & dosage*
  • COVID-19 / diagnostic imaging
  • COVID-19 / drug therapy*
  • COVID-19 / enzymology
  • COVID-19 / genetics
  • Humans
  • Leukemia, Myeloid, Acute / diagnostic imaging
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / enzymology
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Pyrazines / administration & dosage*
  • Remission Induction
  • SARS-CoV-2*
  • fms-Like Tyrosine Kinase 3 / genetics
  • fms-Like Tyrosine Kinase 3 / metabolism

Substances

  • Aniline Compounds
  • Pyrazines
  • gilteritinib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3